Novel CELMoD Agents Mechanism of Action Thumbnail

Novel CELMoD™ Agents as Investigational Treatment for Multiple Myeloma

Phase 3 clinical trials of iberdomide and mezigdomide are currently open for enrollment

Find Out More See how novel CELMoD agents work

Explore Novel CELMoD Trials

Iberdomide phase 3 studies

now recruiting
  • Iber-Dd vs DVd
  • Patients with RRMM and 1-2 priors (not including anti-CD38 mAbs)
See Details
now recruiting
  • Iber vs R
  • Patients with NDMM post-SCT transitioning to maintenance therapy
See Details

Mezigdomide phase 3 studies

now recruiting
  • Mezi-Vd vs Pom-Vd
  • Patients with RRMM and 1-3 priors with lenalidomide exposure
See Details
now recruiting
  • Mezi-Kd vs Kd
  • Patients with RRMM and ≥1 priors with lenalidomide and anti-CD38 mAb exposure
See Details
Clinical Trial Locator Tool Icon

Have a trial identified already?
Find a clinical trial by location

CELMoD=cereblon E3 ligase modulator; D=Darzalex® (daratumumab); d=dexamethasone; Iber=iberdomide; K=Kyprolis® (carfilzomib); mAb=monoclonal antibody; Mezi=mezigdomide; NDMM=newly diagnosed multiple myeloma; Pom=POMALYST® (pomalidomide); R=REVLIMID® (lenalidomide); RRMM=relapsed/refractory multiple myeloma; SCT=stem cell transplant; V=Velcade® (bortezomib).

How Novel CELMoD Agents Work

Please verify that you are a US Healthcare Professional

This information is intended for US Healthcare Professionals

I am a US Healthcare Professional

I am not a US Healthcare Professional

You are about to leave this Bristol Myers Squibb website. You are being redirected to another Bristol Myers Squibb website.

Would you like to leave the website?

You are now leaving this Bristol Myers Squibb website.

You are about to leave this website for another external website. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.